Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Inclusion Criteria: * Premenopausal female aged 18 or older * Diagnosis of uterine fibroids confirmed by transvaginal/rectal ultrasound during the screening period * Heavy menstrual bleeding caused by uterine fibroids * Breast ultrasound results during the screening period meet the BI-RADS classification of 1 to 3 * Able to understand and comply with the study procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing Exclusion Criteria: * History of bilateral oophorectomy, or planned to undergo hysterectomy, bilateral oophorectomy, or other surgical procedures during the study period. * Previous treatment with gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists for uterine fibroids has failed. * History of or current osteoporosis or other metabolic bone disease. * History of malignant tumor within 5 years prior to screening, except for cured skin cancer, basal cell carcinoma, and other localized malignant tumors. * History of drug abuse, alcohol abuse, or drug dependence within 2 years prior to screening. * Presence of an in situ copper intrauterine device (IUD) or a progestin-containing IUD implant/subdermal contraceptive implant during the screening period; subjects who can remove the IUD/subdermal contraceptive implant at least 1 month before enrollment may be allowed to participate. * Baseline bone mineral density Z-score of \< -2.0 at the lumbar spine, total hip, or femoral neck during the screening per…